Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Review Article (Mini-Review)

Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review

Author(s): Ali Ahmadi, Hadi E.G. Ghaleh*, Ruhollah Dorostkar, Mahdieh Farzanehpour and Masoumeh Bolandian

Volume 17 , Issue 3 , 2021

Published on: 28 December, 2020

Page: [173 - 178] Pages: 6

DOI: 10.2174/1573394716999201228215537

Price: $65

Abstract

Cancer is a genetic disease triggered by gene mutations, which control cell growth and their functionality inherited from previous generations. The targeted therapy of some tumors was not especially successful. A host of new techniques can be used to treat aptamer-mediated targeting, cancer immunotherapy, cancer stem cell (CSC) therapy, cell-penetrating peptides (CPPs), hormone therapy, intracellular cancer cell targeting, nanoparticles, and viral therapy. These include chemical-analog conjugation, gene delivery, ligand-receptor-based targeting, prodrug therapies, and triggered release strategies. Virotherapy is a biotechnological technique for turning viruses into therapeutic agents by the reprogramming of viruses to cure diseases. In several tumors, including melanoma, multiple myeloma, bladder cancer, and breast cancer, the oncolytic capacity of oncolytic Coxsackievirus has been studied. The present study aims to assess oncolytic Coxsackievirus and its mechanisms of effect on cancer cells.

Keywords: Cancer, viral therapy, targeted therapy, oncolytic viruses, coxsackievirus, viral vectors.

Graphical Abstract
[1]
Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 2020; 13(1): 84.
[http://dx.doi.org/10.1186/s13045-020-00922-1] [PMID: 32600470]
[2]
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther 2020; 28(3): 709-22.
[http://dx.doi.org/10.1016/j.ymthe.2020.01.001] [PMID: 31968213]
[3]
Castro MG, Candolfi M, Wilson TJ, et al. Adenoviral vector-mediated gene therapy for gliomas: Coming of age. Expert Opin Biol Ther 2014; 14(9): 1241-57.
[http://dx.doi.org/10.1517/14712598.2014.915307] [PMID: 24773178]
[4]
Drayman N, Patel P, Vistain L, Tay S. HSV-1 single-cell analysis reveals the activation of anti-viral and developmental programs in distinct sub-populations. eLife 2019; 8: e46339.
[http://dx.doi.org/10.7554/eLife.46339] [PMID: 31090537]
[5]
Lundstrom K. Viral vectors in gene therapy. Diseases 2018; 6(2): 42.
[http://dx.doi.org/10.3390/diseases6020042] [PMID: 29883422]
[6]
Subramanya S, Kim SS, Manjunath N, Shankar P. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: Synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther 2010; 10(2): 201-13.
[http://dx.doi.org/10.1517/14712590903448158] [PMID: 20088715]
[7]
Baldo A, Galanis E, Tangy F, Herman P. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother 2016; 12(5): 1102-16.
[http://dx.doi.org/10.1080/21645515.2015.1122146] [PMID: 26631840]
[8]
Lee NH, Lee JA, Park SY, Song CS, Choi IS, Lee JB. A review of vaccine development and research for industry animals in Korea. Clin Exp Vaccine Res 2012; 1(1): 18-34.
[http://dx.doi.org/10.7774/cevr.2012.1.1.18] [PMID: 23596575]
[9]
Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG. Oncolytic viruses and immune checkpoint inhibition: The best of both worlds. Mol Ther Oncolytics 2019; 13: 93-106.
[http://dx.doi.org/10.1016/j.omto.2019.04.003] [PMID: 31080879]
[10]
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune conversion of tumor microenvironment by oncolytic viruses: The Protoparvovirus H-1PV case study. Front Immunol 2019; 10: 1848.
[http://dx.doi.org/10.3389/fimmu.2019.01848] [PMID: 31440242]
[11]
Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 2019; 18(9): 689-706.
[http://dx.doi.org/10.1038/s41573-019-0029-0] [PMID: 31292532]
[12]
Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic viruses: Priming time for cancer immunotherapy. BioDrugs 2019; 33(5): 485-501.
[http://dx.doi.org/10.1007/s40259-019-00367-0] [PMID: 31321623]
[13]
Cervera-Carrascon V, Quixabeira DCA, Havunen R, et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors. Mol Ther Oncolytics 2020; 17: 47-60.
[http://dx.doi.org/10.1016/j.omto.2020.03.003] [PMID: 32322662]
[14]
Jayawardena N, Poirier JT, Burga LN, Bostina M. Virus-receptor interactions and virus neutralization: Insights for oncolytic virus development. Oncolytic Virother 2020; 9: 1-15.
[http://dx.doi.org/10.2147/OV.S186337] [PMID: 32185149]
[15]
Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: The dynamic duo. Mol Ther Methods Clin Dev 2020; 17: 349-58.
[http://dx.doi.org/10.1016/j.omtm.2020.01.001] [PMID: 32071927]
[16]
Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol 2017; 7: 195.
[http://dx.doi.org/10.3389/fonc.2017.00195] [PMID: 28944214]
[17]
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14(9): 642-62.
[http://dx.doi.org/10.1038/nrd4663] [PMID: 26323545]
[18]
Phillips MB, Stuart JD, Rodríguez Stewart RM, Berry JT, Mainou BA, Boehme KW. Current understanding of reovirus oncolysis mechanisms. Oncolytic Virother 2018; 7: 53-63.
[http://dx.doi.org/10.2147/OV.S143808] [PMID: 29942799]
[19]
Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: Barriers and recent advances. Mol Ther Oncolytics 2019; 15: 234-47.
[http://dx.doi.org/10.1016/j.omto.2019.10.007] [PMID: 31872046]
[20]
Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: Future prospects for oncology. J Immunother Cancer 2018; 6(1): 140.
[http://dx.doi.org/10.1186/s40425-018-0458-z] [PMID: 30514385]
[21]
Goldufsky J, Sivendran S, Harcharik S, et al. Oncolytic virus therapy for cancer. Oncolytic Virother 2013; 2: 31-46.
[PMID: 27512656]
[22]
Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Linchuang Zhongliuxue Zazhi 2018; 7(2): 16.
[http://dx.doi.org/10.21037/cco.2018.04.04] [PMID: 29764161]
[23]
Khanna M, Gautam A, Rajput R, Sharma L. Natural products as a paradigm for the treatment of Coxsackievirus-induced myocarditis. Curr Top Med Chem 2020; 20(8): 607-16.
[http://dx.doi.org/10.2174/1568026620666200129094516] [PMID: 31995007]
[24]
Cassidy H, Poelman R, Knoester M, Van Leer-Buter CC, Niesters HGM. Enterovirus D68-The new polio? Front Microbiol 2018; 9: 2677.
[http://dx.doi.org/10.3389/fmicb.2018.02677] [PMID: 30483226]
[25]
Rhoades RE, Tabor-Godwin JM, Tsueng G, Feuer R. Enterovirus infections of the central nervous system. Virology 2011; 411(2): 288-305.
[http://dx.doi.org/10.1016/j.virol.2010.12.014] [PMID: 21251690]
[26]
Bopegamage S. Enterovirus infections: Pivoting role of the adaptive immune response. Virulence 2016; 7(5): 495-7.
[http://dx.doi.org/10.1080/21505594.2016.1175701] [PMID: 27058267]
[27]
Okonko IO, Adebiyi AA, Ogah OS, Adu FD. Enteroviruses as a possible cause of hypertension, dilated cardiomyopathy (DCM) and hypertensive heart failure (HHF) in South western Nigeria. Afr Health Sci 2013; 13(4): 1098-106.
[http://dx.doi.org/10.4314/ahs.v13i4.34] [PMID: 24940338]
[28]
Chen X, Liu R, Liu X, Xu C, Wang X. Protective role of coxsackie-adenovirus receptor in the pathogenesis of inflammatory bowel diseases. BioMed Res Int 2018; 2018: 7207268.
[http://dx.doi.org/10.1155/2018/7207268] [PMID: 30175139]
[29]
Patel KP, Coyne CB, Bergelson JM. Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. J Virol 2009; 83(21): 11064-77.
[http://dx.doi.org/10.1128/JVI.01016-09] [PMID: 19710132]
[30]
McCarthy C, Jayawardena N, Burga LN, Bostina M. Developing Picornaviruses for cancer therapy. Cancers (Basel) 2019; 11(5): 685.
[http://dx.doi.org/10.3390/cancers11050685] [PMID: 31100962]
[31]
Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Applications of coxsackievirus A21 in oncology. Oncolytic Virother 2014; 3: 47-55.
[http://dx.doi.org/10.2147/OV.S56322] [PMID: 27512662]
[32]
Newcombe NG, Johansson ES, Au G, Lindberg AM, Barry RD, Shafren DR. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. J Virol 2004; 78(3): 1431-9.
[http://dx.doi.org/10.1128/JVI.78.3.1431-1439.2004] [PMID: 14722298]
[33]
Huang GT, Zhang X, Park NH. Increased ICAM-1 expression in transformed human oral epithelial cells: Molecular mechanism and functional role in peripheral blood mononuclear cell adhesion and lymphokine-activated-killer cell cytotoxicity. Int J Oncol 2000; 17(3): 479-86.
[http://dx.doi.org/10.3892/ijo.17.3.479] [PMID: 10938387]
[34]
Hadac EM, Kelly EJ, Russell SJ. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. Mol Ther 2011; 19(6): 1041-7.
[http://dx.doi.org/10.1038/mt.2011.68] [PMID: 21505425]
[35]
Müller LME, Holmes M, Michael JL, et al. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. J Immunother Cancer 2019; 7(1): 164.
[http://dx.doi.org/10.1186/s40425-019-0632-y] [PMID: 31262361]
[36]
Shafren D, Quah M, Wong Y, Andtbacka RH, Kaufman HL, Au GG. Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. J Immunother Cancer 2014; 2(S3): 125.
[http://dx.doi.org/10.1186/2051-1426-2-S3-P125]
[37]
Yuan M, Wong Y, Au G, Shafren D. Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge. J Immunother Cancer 2015; 3(S2): 342.
[http://dx.doi.org/10.1186/2051-1426-3-S2-P342]
[38]
Annels NE, Arif M, Simpson GR, et al. Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus. Mol Ther Oncolytics 2018; 9: 1-12.
[http://dx.doi.org/10.1016/j.omto.2018.02.001] [PMID: 29989024]
[39]
Annels NE, Mansfield D, Arif M, et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 2019; 25(19): 5818-31.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-4022] [PMID: 31273010]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy